Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
3, 15 Mar
10,14 Some studies have pointed out that there can be associated structural changes in the brain of PACS patients such as a reduction in global brain size, loss of gray matter thickness, and tissue contrast in the parahippocampal gyrus and orbitofrontal cortex, as well as tissue damage to the primary olfactory cortex 15 (Figure 1)
These are uncommon at standard therapeutic doses and typically indicate the dose needs adjustment
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer
US$ 25.54
US$ 20.74
US$ 27.08
US$ 25.14
